Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients

To the Editor: Despite the many therapeutic approaches available for hidradenitis suppurativa, there is still a need for effective medications to treat moderate and severe forms of the disease. In this study, we assessed the efficacy of the oral phosphodiesterase 4 inhibitor apremilast (30 mg, twice a day) in the management of 9 patients with moderate to severe hidradenitis suppurativa (Hurley stage II-III) who had responded poorly to other treatments.

http://ift.tt/2rafqaM